Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders
09 oct. 2024 07h30 HE
|
Vanqua Bio
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy volunteers, VQ-101 was well tolerated and achieved...
Vanqua Bio to Participate in Upcoming Scientific Conferences
18 sept. 2024 07h30 HE
|
Vanqua Bio
CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
Vanqua Bio to Present at Inaugural GBA1 2024 Meeting
20 juin 2024 07h30 HE
|
Vanqua Bio
CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders
09 avr. 2024 07h30 HE
|
Vanqua Bio
- VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase)- The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients ...
Vanqua Bio to Present at the Stifel 2024 CNS Days Conference
13 mars 2024 07h30 HE
|
Vanqua Bio
CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease
27 févr. 2024 07h30 HE
|
Vanqua Bio
Posters to be presented at the AD/PD™ 2024 Conference CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International...
Vanqua Bio Advances Clinical Candidate for Parkinson’s Disease, Expands Leadership Team to Support Further Development
12 déc. 2023 07h30 HE
|
Vanqua Bio
CHICAGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase...
Vanqua Bio to Participate in the Leerink Partners Biopharma Private Company Connect
18 oct. 2023 07h30 HE
|
Vanqua Bio
CHICAGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of...
Vanqua Bio to Present at the Stifel 2023 CNS Day Conference
22 mars 2023 07h30 HE
|
Vanqua Bio
CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of...
Vanqua Bio to Present at the Stifel 2022 CNS Day Conference
24 mars 2022 07h30 HE
|
Vanqua Bio
CHICAGO, March 24, 2022 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29. “Vanqua...